Molecular Partners AG (SWX:MOLN)

Market Cap	140.25M -11.3%
Revenue (ttm)	n/a -29.4%
Net Income	-60.23M
EPS	-1.62
Shares Out	37.40M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,029
Average Volume	17,210
Open	3.610
Previous Close	3.750
Day's Range	3.610 - 3.825
52-Week Range	2.700 - 4.140
Beta	0.63
RSI	52.29
Earnings Date	Mar 12, 2026

About Molecular Partners AG

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (D...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 153
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: MOLN

Financial Performance

In 2024, Molecular Partners AG's revenue was 4.97 million, a decrease of -29.38% compared to the previous year's 7.04 million. Losses were -54.04 million, -12.81% less than in 2023.